A major move is in the offing as Caribou Biosciences Inc (CRBU) market cap hits 431.68 million

A new trading day began on Tuesday, with Caribou Biosciences Inc (NASDAQ: CRBU) stock price down -5.35% from the previous day of trading, before settling in for the closing price of $5.05. CRBU’s price has ranged from $3.44 to $8.59 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


During the last 5-year period, the sales growth of Healthcare Sector giant was 71.11%. Meanwhile, its annual earnings per share averaged -26.40%. With a float of $79.39 million, this company’s outstanding shares have now reached $88.45 million.

Let’s determine the extent of company efficiency that accounts for 158 employees.

Caribou Biosciences Inc (CRBU) Insider Activity

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Caribou Biosciences Inc is 12.10%, while institutional ownership is 77.97%.

Caribou Biosciences Inc (CRBU) Earnings and Forecasts

In its latest quarterly report, released on 12/30/2023, the company reported earnings of -$0.39 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -26.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.50% during the next five years compared to -37.16% drop over the previous five years of trading.

Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators

Here are Caribou Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.52.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -2.06 in one year’s time.

Technical Analysis of Caribou Biosciences Inc (CRBU)

Looking closely at Caribou Biosciences Inc (NASDAQ: CRBU), its last 5-days average volume was 1.54 million, which is a drop from its year-to-date volume of 1.63 million. As of the previous 9 days, the stock’s Stochastic %D was 9.40%. Additionally, its Average True Range was 0.40.

During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 23.33%, which indicates a significant increase from 4.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.50% in the past 14 days, which was lower than the 95.81% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $6.32, while its 200-day Moving Average is $5.67. However, in the short run, Caribou Biosciences Inc’s stock first resistance to watch stands at $4.93. Second resistance stands at $5.07. The third major resistance level sits at $5.18. If the price goes on to break the first support level at $4.68, it is likely to go to the next support level at $4.57. Should the price break the second support level, the third support level stands at $4.43.

Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats

With a market capitalization of 431.68 million, the company has a total of 90,315K Shares Outstanding. Currently, annual sales are 34,480 K while annual income is -102,070 K. The company’s previous quarter sales were 3,560 K while its latest quarter income was -34,510 K.